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ABSTRACT 
With next generation sequencing taking center stage in genetic and epigenetic research, its 
applications and challenges are many. This work revolves around the application of 
bioinformatics in different contexts: basic research in the understanding of diseases (biology), 
the effect of treatment on the target cells (clinics) and the assessment of a new wet-lab 
method (lab). 
Biology Two studies fall under this topic, one on chronic lymphocytic leukemia, the other on 
multiple myeloma. Many coding mutations and chromosomal aberrations have long been 
identified in both diseases, yet they are only present in subsets of patients, and so it is 
puzzling that all this diversity results in a single diagnosis. We hypothesized that instead of a 
common genetic background, they might present with a common epigenetic background. For 
this we aimed to collect paired RNA-seq, histone ChIP-seq and ATAC-seq for patients and 
healthy controls, and had the following specific hypotheses: 
1. Using H3K4me2 and H3K27Ac, we will be able to identify the regulatory elements 
altered between health and disease 
2. By looking at the interplay between those regulatory elemets, RNA-seq, ATAC-seq 
and database information, we will be able to describe the aberrant regulation in terms 
of transciption factors, regulatory elements and their target genes. 
Clinics Ibrutinib is a novel drug used in chronic lymphocytic leukemia treatment. Though it 
is shown to be beneficial to many patients, a lot of the early effects the treatment has on the 
malignant cells, especially in different parts of the body, are still unknown. We 
hypothesized that relevant changes in blood and lymph nodes would be visible soon after 
treatment, and collected RNA-seq data from both compartments, in additions to plasma 
values of inflammatory cytokines. We had to following specific hypotheses: 
1. Early changes are visible, maybe even just hours after first treatment. 
2. There will be differences in treatment effect between blood and lymph node 
compartments. 
Lab ChIP-seq is a very useful method to look at proteins bound to DNA, which, depending 
on the protein checked, can give a multitude of information. Yet, the amount of cells 
needed to perform these experiments is high, even in improved protocols like 
ChIPmentation. We hypothesized that the ChIPmentation protocol could be optimized, and 
that reducing time and steps would yield better data. For this we performed ChIP-seq with 
the original ChIPmentation protocol and with our adaptation, testing the following specific 
hypotheses: 
1. Our version, high-throughput ChIPmentation, will perform equally well as the 
original method when high cell numbers are used, but be faster. 
2. When low cell numbers are used, our method will give better results, as it involves 
less loss of material. 
  
My contribution lies in the development and execution of bioinformatics, pipelines, data 
handling etc, to test these hypotheses, which also includes discussions and planning of 
projects, samples and feasibility. 
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1 B-CELLS 
All studies included in this work are related to B-cells, be they healthy or diseased, primary or 
cell lines. Hence, it seems only reasonable to give them a little introduction.  
1.1 ROLE 
B-cells are lymphocytes (Figure 1) responsible for antibody (Ab) production. Abs bind to 
antigens, any recognizable structure, and in this way flag unknown agents to the rest of the 
immune system. In order to react with as many foreign antigens as possible, the B-cell 
population in a healthy individual is made up of thousands of clones. All of these clones are 
genetically different and produce slightly different Abs. The genetic differences observed in 
B-cell clones are accomplished by recombination of the immunoglobulin (Ig) regions, the 
genetic regions that code for Ab parts. Thus, in contrast to most other cell types, which all 
have the exact same genome, B-cells undergo genome editing. 
 
 
 
 
Figure 1: Simplified overview of the hematopoietic system in humans. 
Figure adapted from creative commons illustration by A. Rad1. 
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1.2 B-CELL ACTIVATION 
When a mature, naïve B-cell (NaïveB), binds an antigen by use of its B-cell receptor (BCR), 
the cell becomes activated (Figure 2). 
 
 
Figure 2: B-cell activation. NaïveB = mature, naïve B-cell, BCR = B-cell receptor, nsMemB = non-switched 
memory B-cells, sMemB = switched memory B-cells. Figure used elements from creative commons illustration 
by A. Rad1 
 
Activated B-cells will make their way to the germinal center (GC) in the lymph nodes. Here 
they undergo GC reaction, resulting in somatic hyper mutation of the Ab part regions in their 
genome. The goal is to create a B-cell clone that reacts even better with the antigen that 
caused the activation, and thus perfect the immune reaction. A part of these perfected B-cells 
will become plasma cells, which are bigger, and optimized for producing high numbers of 
secreted Abs. These circulating Abs will bind to the agent that triggered the immune reaction, 
cluster together and flag them for destruction by other immune cells. Other activated B-cells 
will become memory B-cells, which will stay in the body and, in case of a second infection 
with the same agent, will be ready for a fast, targeted immune reaction. These memory B-
cells can still have IgM and IgD Abs, as the original mature B-cell had, or switch to IgE, IgG 
or IgA Abs, referred to as non-switched memory B-cells (nsMemB) and switched memory B-
cells (sMemB) respectively2. 
Antigen
BCR / antibody
NaïveB Activated B-cell
+
Plasma cell
nsMemB
sMemB
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2 TRANSCRIPTIONAL REGULATION 
In order for cells to function properly, they need strict regulation of what genes are expressed, 
and when and where this happens. 
2.1 REGULATORY ELEMENTS  
Eukaryotic, protein-coding genes generally have two types of regulatory DNA elements: 
promoters and distal regulatory elements. The later include elements such as enhancers and 
insulators3. In order for these to fulfill their roles at the right time and place, they interact with 
transcription factors (TFs), which will be discussed in a later section. 
2.1.1 Promoters 
Promoters are regulatory elements located right at the transcription start site (TSS) of the 
gene they regulate. Promoters are usually made up of a core promoter and a proximal 
promoter3. The core promoter is the region that stretches about 35 base pairs (bp) up- and/or 
downstream of the gene's TSS and is the docking site for basic transcription machinery like 
RNA polymerase II (PolII)4. The region directly upstream of the core promoter is the 
proximal promoter, which is made up of the regulatory elements that fall up to a few hundred 
bp away from the core promoter3. These regulatory elements contain binding sites for TFs 
regulating the expression of the gene in question (Figure 3A and B). 
2.1.2 Distal regulatory elements 
Enhancers are regulatory regions containing a set of TF binding site collections that can 
increase the transcription of a gene, which makes them very similar to proximal promoters3. 
The biggest difference is the distance at which they operate. While promoters are just 
upstream of the TSS, enhancers can be hundreds of kilobases away and located anywhere in 
the non-coding part of the genome. This means they can be up- or downstream of the gene, or 
even within a gene body. However, to exert its regulatory effect, the enhancer needs to be 
brought into proximity of the promoter of its target gene, which is done by looping out the 
DNA that separates them (Figure 3C). The result is that both are still far away in linear 
sequence, but close in 3D space. Though the direction of the whole enhancer is not critical for 
its function, the enhancer might only be able to regulate its target gene if the different parts 
that make up the enhancer are correctly positioned relative to one another.  
2.1.3 Super-enhancers 
In addition to these regular enhancers, usually a few kilobases in size5, larger regions with 
multiple regular enhancers clustering together in close proximity have been identified and 
termed super-enhancers (SE). Though there is still discussion on whether they are a separate 
type of regulatory elements or rather a collection of regular enhancers6, SE are often linked to 
cell type specific genes, making them important for cell identity7,8. SE have also been 
associated to disease8,9, and the fact that they are easily disrupted might make them 
interesting drug targets10,11. 
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Figure 3: Representation of DNA, regulatory elements and transcription factors. 
 
2.2 TRANSCRIPTION FACTORS 
Transcription factors (TFs) are proteins that change the expression of genes. They can either 
enhance or repress expression and as a result are respectively called activators or repressors5. 
They can also be organized based on their way of interacting with regulatory elements3. 
General transcription factors (GTFs) interact directly with the core promoter of a gene, and 
are the minimum TFs needed for basal transcription. They include RNA polymerase II and 
other factors that make up the pre-initiation complex. The resulting basal transcription is not 
particularly high or regulated, but can be altered by activators and repressors. This second 
group of TFs directly binds DNA sequences of about 6-12bp, called motifs or binding sites, 
in enhancers and proximal promoters3,5 (Figure 3B). They are classified into TF families based 
on the motif they recognize and the domain structure that binds it12. In addition to a DNA 
binding domain, activators also have an activation domain required for enhancing the 
transcription of their target gene5. Repressors on the other hand usually work by blocking 
activators or GTFs from binding their motifs. The last group of TFs is that of the co-
activators and co-repressors. These TFs do not have DNA binding domains themselves, but 
interact with activators and repressors to regulate transcription3. 
promoterdistal regulatory element
TSS
several 100 bpseveral 100 000 bp
DNA
TSS
TF binding site
TFs
Pol II
RNA
A
B
C
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The resulting set-up can be rather complex, and the correct regulation of a gene generally 
requires multiple TFs to exert their function in the right time and place. Though multiple 
models exist5, this usually means the TFs need to be expressed and available at the right 
level, their motifs need to be free for binding and all interacting partners need to be present at 
that moment, in that location. 
2.3 EPIGENETICS 
The regulatory elements described above are not based solely on DNA sequence (Figure 4). 
After all, all cells in the body, with some exceptions like B-cells, have the exact same 
genome, yet perform very different functions. For this, genomic regions can be activated and 
deactivated, guiding regulatory elements and TFs depending on the cell’s need. This is where 
epigenetics comes into play. In B-cells, for example, processes all the way from general 
hematopoiesis13, to B-cell specific events like Ig recombination14,15, GC reaction and 
transition to memory B-cells16–18, have been linked to epigenetic changes or regulation. 
2.3.1 Definition 
Though the term "epigenetics" is frequently used, definitions of what it actually means vary 
widely. The oldest definition is made by Waddington, who based it on "epigenesis", being 
"the concept that an organism develops by the new appearance of structures and functions, as 
opposed to the hypothesis that an organism develops by the unfolding and growth of entities 
already present in the egg at the beginning of development (preformation)" 19. As a result, in 
this definition epigenetics includes all molecular mechanisms “by which the genes of the 
genotype bring about phenotypic effects”, or basically anything that influences gene 
expression.  
A stricter definition by Riggs makes the limitation that these changes need to be heritable, 
making epigenetics "the study of mitotically and/or meiotically heritable changes in gene 
function that cannot be explained by changes in DNA sequence" 20. Originally this only 
included DNA methylation, but some authors have also included more concepts like 
prions 21, being heritably misfolded proteins.  
More recently, intermediate definitions have been suggested, including the one by Bird, who 
considers epigenetics to be "the structural adaptation of chromosomal regions so as to 
register, signal or perpetuate altered activity states" 22. This definition includes DNA 
methylation, but also heritable or transient histone modifications, which might only come 
about in specific stages of a cell's existence.  
This work uses the last definition, which is, notwithstanding the lack of consensus, at least a 
common use of the term epigenetics23–25. As DNA methylation is the bread and butter of 
epigenetics, and histone modifications are the main focus of the included papers, those will 
be described a bit further. 
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Figure 4: Overview of DNA organization, epigenetic marks and regulatory elements. 
Originally published by Ecker et al.26, reproduced with permission from Nature. 
 
2.3.2 DNA methylation 
Cytosin (C) bases in the genome can be methylated by DNA methyltransferases. As a result, 
about 1% of the bases in the genome are 5-methylcytosine (5mC)27. This 5mC can 
spontaneously deaminate to a thymine (T) base28. It is speculated that this process is the basis 
for the observation that the genome generally has a higher AT than GC content. However, 
some regions in the genome are unmethylated while particularly GC rich. Due to their 
specific enrichment for a dinucleotide made up of C followed by G (CpG), these regions are 
called CpG islands. This specific DNA composition could destabilize the packing of the 
DNA in that region, making it more accessible for transcription29. CpG islands comprise 
about 1% of the mammalian genome30 and harbor roughly 70% of TSS in humans31,32. 
Highly expressed genes tend to have unmethylated core-promoters and a methylated gene 
body33, repressing incorrect transcription starting in the middle of a gene. When DNA at 
promoter or regulatory regions gets methylated, this interferes with proper expression and the 
associated gene is silenced34. However, the lack of DNA methylation does not necessarily 
mean a gene will be expressed. Both housekeeping genes, which are generally expressed, and 
tissue-specific genes can have their TSSs in unmethylated CpG islands, which would favor 
their expression, and still not be expressed in that moment and tissue35. 
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2.3.3 Histone modification 
In the eukaryotic genome, DNA is organized and compacted by winding around histones. A 
histone is an octamer, made out of four basic histone proteins: H2A, H2B, H3 and H4. 
Histone modifications are post-translational modifications to the tails of these histone 
proteins. There are at least twelve types of histone modifications, including methylation and 
acetylation, which can occur at a wide variety of residues within the histone tails24. As a 
result, the nomenclature of histone modifications is based on the type of modification and its 
location. For example, H3K27Ac refers to acetylation (Ac) on the lysine (K) residue that is in 
the 27th position in the tail of the histone protein H3. In addition to modifications to the four 
basic histone proteins, variants of these proteins have been observed, resulting in even higher 
diversity. The sum total of all these possible states has been termed the histone code36.  
The histone code exhibits general patterns, and distinct features in the genome display 
different set-ups in their histone code. Acetylation of histone tail residues is related to active 
regions of the genome and thus can be found on active enhancers and promoters. Methylation 
can be observed in either active or repressed regions, depending on the level of methylation 
and the exact residue involved25. For example, active promoters are shown to be enriched in 
H3K4me3 to a degree correlated to their expression37 but are repressed when marked with 
H3K27me3 instead38. Looking at combinations of histone marks can give additional 
information. It has been shown that combining H3K4me2 and H3K27Ac marks can reduce 
false positives when predicting TF binding39. 
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3 CHRONIC LYMPHOCYTIC LEUKEMIA & MULTIPLE 
MYELOMA 
All blood lineages are challenged by cancers (Figure 5). Chronic lymphocytic leukemia (CLL) 
and multiple myeloma (MM) are part of the B-cell malignancies. 
 
 
Figure 5: Simplified overview of the hematopoietic system in humans, with examples of malignancies in each 
lineage. Figure adapted from creative commons illustration by A. Rad1. 
 
Table 1: Estimated US cases in 2018 (by sex) for all cancers, lymphoma, multiple myeloma and leukemia40 
  Estimated new cases Estimated deaths 
  M & F M F M & F M F 
All sites 1,735,350 856,370 878,980 609,640 323,630 286,010 
Lymphoma 83,180 46,570 36,610 20,960 12,130 8,830 
Hodgkin lymphoma 8,500 4,840 3,660 1,050 620 430 
Non-Hodgkin lymphoma 74,680 41,730 32,950 19,910 11,510 8,400 
Myeloma 30,770 16,400 14,370 12,770 6,830 5,940 
Leukemia 60,300 35,030 25,270 24,370 14,270 10,100 
Acute lymphocytic leukemia 5,960 3,290 2,670 1,470 830 640 
Chronic lymphocytic leukemia 20,940 12,990 7,950 4,510 2,790 1,720 
Acute myeloid leukemia 19,520 10,380 9,140 10,670 6,180 4,490 
Chronic myeloid leukemia 8,430 4,980 3,450 1,090 620 470 
Other leukemia 5,450 3,390 2,060 6,630 3,850 2,780 
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Figure 6: Estimated new cases of MM and leukemia (including CLL) in 2018 (incidence)41,42. World maps show 
estimated age-standardized incidence rates worldwide in 2018, including both sexes and all ages, and their 
visualization was made with Paintmaps43. Note that the scale for both world maps is different, but that the 
Leukemia one includes more than just CLL. Absolute incidence is from the same source, but not age-
standardized. Lifetime risk estimates are US based, gathered from respective pages on the American Cancer 
Society website: CLL44, MM45. 
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3.1 CLL  
CLL is the most common leukemia in adults in the western world, representing roughly 1/3rd 
of leukemia incidence and 1.2% of total cancer incidences in the United States40 (Table 1). 
CLL incidence is higher in men than women, and multiple other risk factors are recognized 
(Table 2). Usually, CLL is diagnosed in a routine blood test, since it manifests as B-
lymphocytes coming from one single B-cell clone accumulating in the peripheral blood, 
lymph nodes and bone marrow, even if no symptoms are apparent. However, small 
expansions of multiple B-cell clones are normal in elderly people, and do not need to result in 
CLL. If these small clones do continue to expand and select, this can turn into monoclonal B-
cell lymphocytosis (MBL), and later on into CLL. The biggest distinction made within CLL 
is based on the level of mutations in the IGHV region of the Ab part genes. Patients with low 
mutational load in this region are called un-mutated CLL (U-CLL), while patients with high 
mutational load are called mutated CLL (M-CLL). This distinction is believed to be related to 
the B-cell of origin, and is not to be confused with the absence or presence of recurrent 
mutations in other regions of the genome. 
Though CLL patients can go without symptoms for years, over time the expanding B-cell 
clone outcompetes the other blood cell lineages, resulting in anemia and infections that lead 
to the patient’s death. Treatment is usually antibody therapy in combination with 
chemotherapy, but unless bone marrow transplantation is possible, CLL remains incurable.  
Commonly, a watch and wait approach is taken, delaying treatment as long as possible to 
avoid side effects and selective pressure of therapy risking future expansion of more 
aggressive clones. 
3.2 IBRUTINIB IN CLL 
As Ibrutinib is central in one of the studies included in this work, this section provides some 
more information on this drug. Though also used in other hematopoietic malignancies, its use 
in CLL was approved in 2014 in the US and Europe46. Initially this was only for previously 
treated patients, but by now it has been approved as monotherapy in first-line treatment47. 
Both as combination (HELIOS trial)48 and monotherapy (RESONATE trials)49,50, Ibrutinib 
has been shown to be more effective than standard treatment. Side effects are assessed to be 
tolerable, though alternatives might be preferred if one has specific other conditions47. 
Ibrutinib irreversibly binds, and thus inhibits, the Bruton’s tyrosine kinase (BTK), which is 
one of the enzymes active in B-cell receptor signaling. Though healthy B-cells also use this 
pathway, Ibrutinib preferably kills CLL cells rather than healthy cells51, and reduces tumor 
proliferation and load in blood, lymph nodes and bone marrow52. Because of this disruption 
of signaling, Ibrutinib induces sizable redistribution lymphocytosis, were cells resident in 
lymph nodes get released into the blood, resulting in a rise in absolute lymph counts in 
blood53. However, this seems to be harmless and reduces with further treatment. 
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3.3 MM 
Like CLL, MM is most common in highly developed countries, representing about 0.9% of 
cancer incidences in the world41,42 (Figure 6), but 1.8% of cancer incidences in the United 
States40 (Table 1). Risk factors are shared with CLL (Table 2), again with higher incidence in 
men than women. While CLL probably originates in mature B-cells, somewhere around 
naïve and memory B-cells, MM originates somewhere around memory and plasma cells. 
Small clonal plasma cell expansions can grow into monoclonal gammopathy of undetermined 
significance (MGUS) and continue to MM. 
Diagnosis can be based on end-organ damage, were patients might have pain in bones due to 
lesions, feel exhausted due to anemia or present with kidney failure54. Even without damage, 
the presence of expanded clones, accumulation of monoclonal protein levels and biomarkers 
can be sufficient for diagnosis. 
 
Table 2: Overview of some of the risk factors and symptoms observed in CLL and MM. 
 CLL MM 
Risk 
factors 
 
• Advanced age (>65) 
• Male 
• White-American  
(vs other American 
backgrounds)55 
• Family with CLL56 
• Being a farmer 
(insecticides)57 
• Exposure to Agent Orange58 
 
• Advanced age (>65) 
• Male 
• African-American  
(vs other American 
backgrounds)59 
• Family with MM60 
• Being a farmer 
(unknown exposure)61 
Symptoms 
Often none, otherwise e.g.: 44,62 
• Anemia => tired,… 
• Leukopenia => infections,… 
• Enlarged spleen/liver 
=> feeling full 
• Swollen lymph nodes 
CRAB features: 54,63,64 
• hyperCalcemia 
=> dehydration,… 
• Renal failure => weakness,… 
• Anemia => tired,… 
• lytic Bone lesions => pain,… 
 
3.4 GENETIC CHANGES IN CLL & MM 
Both CLL and MM present a range of genetic aberrations. They differ not only compared to 
healthy individuals, but also between each other, and between individuals with the same 
disease. CLL displays a number of recurrent mutations and acquired genomic copy number 
variations (aCNVs), all present in less than half of patients, and the genetic diversity in MM 
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is a lot higher still. Charting changes is not only interesting for understanding the disease, but 
bears great potential for individualized medicine. 
3.4.1 SNPs with increased risk 
Single nucleotide polymorphisms (SNPs) are normally occurring differences in genetic code 
between individuals. These variations are the basis of what makes one person different from 
another, encoding normal things like hair color. They are inherited and are present in all cells 
of the individual. This is in contrast to tumor specific mutations, which are errors, introduced 
in a single cell of an organism by, for example, irradiation. However, even though SNPs are 
inherited, normally occurring and in the whole body, they can still result in an increased risk 
for specific diseases like MM65 and CLL. In the case of CLL, a SNP linked to the micro-
RNAs mir-15a and mir-16-1 has been linked to familial CLL, and many other genes like 
IRF4 and LEF1, known to be aberrantly expressed in CLL, are shown to be associated with 
SNPs. This is not only important for inheritance, but also in trying to understand the disease, 
as supposedly unaffected tissue from the same patient, like nails, saliva or other available 
cells, is often used as control to look for tumor related mutations. 
3.4.2 Recurrent mutations 
One way of altering a gene's expression or effect is by mutating single base pairs from one 
base to another, altering the genetic code. Mutations can be coding or non-coding, 
respectively falling within or outside of the coding part of a gene. When a coding mutation 
results in an amino acid change of the coded protein, it is called non-synonymous. When the 
mutation has no effect, it is called silent. Silent mutations accumulate in normal cells by 
errors during cell division, or by damage inflicted by mutagens like UV radiation. However, 
cancer cells can have a particularly high load of mutations, as DNA repair and pathways that 
lead to programmed cell death are often compromised as part of a cell's transition to cancer.  
Coding On average, a single CLL genome displays around 1000 mutations, and about 10-20 
of these fall in coding regions and are non-synonymous66,67. For MM the number of 
mutations is reported to be around 7450, of which 35 non-synonymous68. On a patient 
population basis, most of these mutations are rare, with only a few mutations recurring in 
>15% of patients, and numbers vary between studies. Some of the most frequent mutations in 
CLL are SF3B1, ATM, TP53, NOTCH1 and MYD8869 (Figure 7), while for MM some are 
KRAS, NRAS, FAM46C, DIS3 and TP5370. However, these mutations are not restricted to 
CLL or MM, and factors like age and treatment influence the observed frequencies. Even 
within a patient, variant allele frequency (VAF), or the frequency at which the mutation is 
found compared to the wild type allele, can be low, indicating the mutation is more likely to 
be related to progression than onset of the disease, if it is relevant at all.  
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Figure 7: Frequencies of most common genetic events in CLL69. Summarizes data from the different datasets 
(top), different treatment history (black = treated, white = treatment naïve) and IGHV mutational status  
(white = U-CLL, black = M-CLL, red = unknown). Originally published by Landau et al., and reproduced with 
permission from Nature. 
 
Non-coding Non-coding mutations provide an additional challenge, as putting them into their 
genetic context and finding possible effects is not straightforward. In CLL recurrent 
mutations have been identified in the 3’ region of NOTCH1 and in an enhancer of PAX571. A 
recent study in MM, using promoter capture Hi-C to link non-coding mutations to target 
regions, also describes PAX5 targeting, among others72. 
3.4.3 Chromosomal aberrations 
Genetic changes can be a lot bigger than point mutations, as large parts of the genome can for 
example be deleted, duplicated or rearranged. These chromosomal aberrations, also called 
aCNV, are particularly frequent in cancer compared to normal cells and can affect multiple 
genes at once. Normally these changes would result in cell death, but the tumor suppressor 
genes needed for apoptotic programs are often among the ones affected in these cells. 
CLL The four most common aCNVs in CLL are deletions on chr13 (del13q14), chr17 
(del17p) or chr11 (del11q), and trisomy of chr12 (tri12) 67,73. At diagnosis, del13q14 is found 
in about 50% of CLLs, making it the most frequent aCNV. Because of this, it is considered 
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important for CLL and considered a driver for pathogenesis. However, this identical deletion 
is also found in MM, other blood cancers and even solid tumors, making it unlikely that 
del13q14 causes CLL specific properties or is sufficient to cause CLL. The minimally deleted 
region includes two micro-RNAs, miR-15-a and miR-16-1, which are frequently down-
regulated in CLL74 and linked to TP53 and ZAP7075. The second most frequent aCNV at 
diagnosis is tri12 and is detected in about 15-18% of CLLs. Given that, unlike deletions, it is 
not bound to a very specific region in the genome, it is harder to study and the least 
understood of the recurrent aCNVs. It seems to be mutually exclusive with del13q14 and is 
present in roughly half of the NOTCH1 mutated cases. The third most frequent aCNV is 
del11q. It is detected in 10-15% of CLL cases upon diagnosis, results in the deletion of the 
ATM gene and nearly all cases belong to the U-CLL subgroup. The last frequent aCNV is 
del17p, present in 7-10% of CLL cases and also recurrently deleted in MM and other cancers. 
It always includes the deletion of TP53 on at least one allele, and the remaining copy is 
mutated in virtually all cases. About 80% of CLL patients have at least one of these four 
aCNVs 73, and although a range of less frequent aCNVs can occur, only about 20% of CLLs 
have 3 or more aCNVs. Thus, albeit diverse between patients, CLL is considered a rather 
stable disease. 
MM As compared to CLL, MM can be very complex, even within a patient. In addition to 
del13q14 and del17p shared with CLL, MM also presents with common deletions on 
chromosomes 1, 6, 8, 11, 14 and 16 and gains on chromosomes 1, 12 and 1776. Also the 
absence or addition of whole sets of full chromosomes is common, leading to aberrant states 
of hyperhaploidy (24–34 chromosomes), hypodiploidy (35–45 chromosomes), hyperdiploidy 
(47–57 chromosomes) and hypotriploidy (58–68 chromosomes) 76–78. Also translocations are 
common in MM, in which parts of the chromosomes are relocated. The two most frequent are 
t(11;14), and t(4;14), respectively present in 14% and 11% of patients76. Both of these events 
involve chromosome 14, as this is where IGH genes are located. Because of the importance 
of antibodies in the workings of B-cells, they are heavily expressed, and thus translocation to 
these regions can cause dramatic overexpression of the relocated genes, as they can highjack 
the strong enhancers present there. The fact that the regions need to be rearranged during 
normal B-cell development, to create a repertoire of antibodies, makes them a natural weak 
spot for errors, some of which may lead to MM79. 
3.5 EPIGENETIC CHANGES IN CLL & MM 
With whole genome sequencing methods becoming more available, more and more studies 
look at the epigenetics behind CLL and MM. For this work, the main interest is the 
transcriptional regulation side of this research area, rather than, for example, DNA damage 
repair systems. As in the previous chapter, DNA methylation will be introduced for its central 
role in the concept of epigenetics, and histone modifications for their role in the papers 
included in this work. 
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3.5.1 DNA methylation 
Altered DNA methylation is a general phenomenon in cancer80. It has long been recognized 
that cancers show general hypomethylation, a loss of overall methylation levels in the 
genome81. Given that methylated regions are silenced, a general loss of silencing results in 
aberrant activation of regions, making them more prone to instability, and opening the way to 
cancer82. To add insult to injury, specific sites, like promoters of tumor suppressor genes, get 
hypermethylated, silencing them and removing their ability to control the tumor83. 
CLL A lot of research effort has gone into describing and understanding DNA methylation in 
CLL. As with cancer in general, CLL presents with global hypomethylation84. More 
disordered methylation patterns are linked to worse outcome, and hypothesized to add 
another level of genetic instability, giving the CLL clone more options to gain fitness and 
expand85. In addition to general disruption, many regions consistently gain or lose 
methylation in CLL compared to healthy controls, and U-CLL and M-CLL have 
distinguishable methylation patterns in line with their assumed cells of origin84,86. In fact, 
DNA methylation studies suggest CLL is more of a disease continuum derived from any time 
point in the B-cell maturation process, rather than a binary disease derived from just naïve or 
memory B-cells87. 
MM The situation is very similar for MM, though some patients have been described to show 
global hypermethylation88. In line with the extensive list of genetic events, MM displays 
more heterogeneity in DNA methylation than other hematopoietic malignancies, including 
CLL88. Still, many recurrent changes are found, and a plethora of genes and pathways are 
shown to be affected by altered DNA methylation89. In the non-coding genome, binding sites 
of under-expressed B-cell TFs falling in enhancers were found to be hypermethylated, as if 
they had been decommissioned after the TF expression was down-regulated88.  
3.5.2 Histone modifications 
Many aberrant histone modifications, be they global or local, have been described in cancer, 
leading to the suggestion of the term “histone onco-modifications”90. They include many 
different histone marks, and influence not just gene expression, but also genomic stability, 
DNA repair and cell cycle checkpoints.  
CLL As with genetic changes, aberrant histone modifications are yet another way to disrupt 
genes in cancer. For example, the microRNAs involved in del13 can also be silenced by 
histone deacetylases (HDACs)91. These epigenetic modifiers are overexpressed in CLL, and 
removing them with an HDAC inhibitor (HDACi) is shown to kill CLL cells92. HDACs do 
not work on one site only, and thus it is not surprising that HDACi treatment influences the 
histone acetylation levels of many genes of interest in CLL93. On a more global level, a 
recent, large scale study published histone ChIP-seq for 107 CLL patients94, significantly 
adding to the data available on this topic. In line with DNA methylation findings, U-CLL and 
M-CLL are distinguishable on H3K27ac level, with many regulatory regions being 
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selectively active in one or the other, showing varying states of overlap with different healthy 
B-cell populations. 
MM Also in MM the genetics links back to the epigenetics. The gene NSD2 (also known as 
MMSET) for example, is the target of the t(4;14) translocation, resulting in its up-regulation 
in MM patients with this aberration. Since NSD2 is an epigenetic modulator, its up-regulation 
changes levels of H3K36 and H3K27 methylation, resulting in a more open state95, which is 
in line with the global DNA hypomethylation. Like in CLL, HDACi are of interest in MM 
research, and in this case even approved for therapy96, highlighting the importance of histone 
modifications. On a local scale, B-cell enhancers with aberrant DNA hypermethylation in 
MM were shown to have high levels of the expected histone modifications (H3K4me1, 
H3K27ac) and DNase sensitivity in a MM cell-line88.  
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4 METHODOLOGICAL CONSIDERATIONS 
This sections serves as a complement to the materials and methods in the included works. It 
presents a selection of topics, discusses the related methodological choices, and contrasts 
differences between the studies. 
4.1 METHODS OVERVIEW 
The following figures (Figure 8 to Figure 11) give a schematic overview of the projects, and my 
contribution to them (bright green = hands on, pastel green = varying degrees of providing 
code, coaching or discussion). For the sake of clarity, many side analyses, extra tests for 
reviewers and other work that did not make it into the final papers are not represented. 
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Figure 8: Overview of the CLL project. 
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Figure 9: Overview of MM project. 
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Figure 10: Overview of Ibru project. 
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Figure 11: Overview of HTCM project. 
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4.2 PATIENT CHARACTERISTICS 
As all studies are rather exploratory and small scale, the number of patients included in each 
study is small (Table 3). The number of normal controls is even more limited, but multiple 
normal B-cell populations were sorted from each donor, bringing the total number of control 
samples up, and covering both interpersonal and inter-population variation. In the HTCM 
study only the MEC1 cell line was used, so the only variation there was technical. 
Table 3: Basic information of the samples included in the different projects. 
 
CLL MM Ibru HTCM 
 
case ctrl Case ctrl case ctrl case ctrl 
Total (n) 23 5 23 4 7 3 
 Male (n) 12 4 14 1 6  ? 
  Female (n) 11 1 9 3 1  ? MEC1 cell line 
Treated? mix - No - yes - 
  Age (y) 37-76 >60 49-91 NA  57-77 >60 
  
 
4.2.1 Sex and gender balance 
The sex of the included subject was not part of the design. For patients in the CLL and MM 
studies, the balance is acceptable, especially given that both conditions are more common in 
men. For the Ibru study, men are over represented among patients. In case of healthy controls, 
which were de-identified before we received the samples, there was no possibility to know 
the sex of the subjects, until samples were sequenced and we could deduce sex from the read 
coverage on the Y chromosome (for which we found ChIP-seq data more effective than 
RNA-seq). Even then, we did not exclude samples based on this criteria, and simply used all 
available controls. The healthy controls from the Ibru project were also included in the CLL 
project. No enquiry was done with respect to the gender the subject identified with. 
4.2.2 Geographical origin  
The MM patients included in the study came from 3 different centers, two in the US and one 
in Sweden, while normal controls were from US only. No obvious bias was visible, so no 
specific analysis was performed to describe geographical differences. The fact that not only 
local patients were involved does make the dataset more reflective of real life. Patients in the 
CLL and Ibru studies, as well as healthy controls, were from Sweden. The HTCM study was 
performed on the MEC1 cell line, completely removing personal variation between samples. 
No enquiry was done with respect to the ethnical background of the subjects. 
4.2.3 Prior treatment  
The CLL study includes more personal variation when it comes to treatment, as some patients 
had been treated before, and others had not. Patients in the Ibru study had all been treated 
with other agents prior to Ibru treatment for this study, though the number of regimes varied. 
MM patients were all treatment naïve at the time of sampling, and so this study is most 
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representative of disease basics, without interference of prior treatment, However, it also 
means the findings might be less relevant to real-world patients that have undergone prior 
treatment regimes.  
4.3 CHOICE OF METHODS AND MARKS 
4.3.1 Cell sorting 
One of the major strengths of the included work is that all samples were carefully FACS 
sorted, rather than, for example, solely bead enriched. This higher purity results in improved 
comparisons between populations later on, as it reduces false positive or false negative 
differences caused by contamination with other cells. Even in the HTCM study, where only 
the MEC1 cell line was used, samples were still sorted for live cells. It is important to keep in 
mind though that all handling of cells will stress them, and possibly cause regulatory changes. 
4.3.2 Histone ChIP-seq marks 
In the CLL and MM paper, histone ChIP-seq was to locate regulatory regions in all samples, 
assess their activity and identify differences between patients and healthy controls. For the 
CLL paper, we selected the histone marks H3K4me2, for its marking of enhancers and 
promoters38, and H3K27ac to distinguish active from poised regulatory elements38,97. Using 
them together can give extra insight39 and both marks are often present in research 
characterizing the histone landscape13,38. An even better distinction could have been made 
had we identified enhancers and promoters separately, by use of H3K4me1 and H3K4me3 
instead of H3K4me2. However, given that the focus of the paper was on gene regulation, the 
most important information was to know the activity of the elements, and thus H3K27ac took 
center stage in the CLL paper, and was the only mark interrogated for the MM paper. In the 
HTCM study, H3K27ac was used to test the new method’s performance on histone 
modifications, as the antibody has high ChIP efficiency and we have ample experience with 
it, reducing technical variation of sources other than the tested method itself. 
4.3.3 High-throughput ChIPmentation 
A clear limitation of regular ChIP-seq is the amount of input cells needed. In both the CLL 
and MM projects, we aimed to have RNA-seq, ChIP-seq and ATAC-seq from all included 
patients and controls. However, there is always a limited amount of sample available, and in 
case of the normal controls, sorting of multiple populations from the same sample further 
reduced available material. At the end of 2015, and alternative ChIP-seq method named 
ChIPmentation (CM), because of its use of tagmentation for ChIP-seq, was published98. We 
did not have this method set up in the lab during the data generation of the CLL and MM 
papers, but started using and developing it for other projects. By further optimizing the CM 
protocol, we developed an even faster and easier version: high-throughput ChIPmentation 
(HTCM). If the experiments for the CLL and MM studies would be performed now, we 
would use this protocol, which might have allowed us to create a more complete dataset from 
the samples that were available at the time. 
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4.3.4 ATAC-seq vs TF ChIP-seq 
In order to build the regulatory networks in the CLL and MM study, we needed to identify 
the presence of TFs and connect them with their possible gene targets. We opted to use 
ATAC-seq instead of individual TF ChIP-seq. As ATAC-seq indicates open chromatin and 
unprotected DNA, it can be used to identify regions were TFs might be binding. While 
greatly simplifying lab work thanks to high throughput and universal data, the main drawback 
of ATAC-seq for this use is that it does not give a direct answer as to what is occupying the 
identified space, and additional info is needed to make a best guess of the specific TF(s) 
present (Table 4). To make a best guess of the occupying TF, we have used overlap with motif 
scans based on the TRANSFAC database. However, it still means the analysis depends on 
previously described and ChIPped TFs present in a database, making it vulnerable to 
technical errors and complications due to biological redundancy of the TF binding sites.  
Table 4: Comparison between TF ChIP-seq and ATAC-seq for assessing TF binding. 
TF ChIP-seq ATAC-seq 
Χ know only what you chip 
(low-throughput) 
þ know all occupied regions at once 
(high throughput) 
Χ dependent on availability and 
quality of anti-body 
þ no anti-body optimizations needed 
Χ TF presence is only info you get þ could be used to look at histone 
occupancy 
þ know that this exact TF is present 
there 
Χ needs extra data to figure out what 
could be occupying the space 
 
Keeping in mind the relative high-throughput of the developed HTCM method, large scale 
TF ChIP-seq is more realistic, though the availability of anti-bodies remains a limiting factor. 
4.3.5 Whole ATAC-seq peaks vs footprinting 
Small, protected regions can be found within ATAC-seq peaks. These are considered 
footprints (FPs), the actual locations were TFs are binding and thus very locally protect the 
DNA, which can be queried on a genome-wide scale99. 
The CLL paper originally relied on HOMER motif enrichment within the whole ATAC-seq 
peaks, but after the use of FP in the MM study, the approach was reconsidered. In the CLL 
dataset, the median ATAC-seq peak is 172 bp, while for FPs this is 18 bp, so reducing the 
searching space seems appropriate. In line with the MM paper, FPs were called from ATAC-
seq data. However, sequencing depth of the ATAC-seq was considerably lower in the CLL 
paper, meaning we had to pool CLL and normal control samples to reach a depth suitable for 
footprinting. In the MM paper, samples were kept separately, but only ones with high 
sequencing depth were considered. Scanning the reference genome for TF motifs resulted in 
putative TF binding sites (TFBSs). For both the CLL and MM paper, a TF showing a TFBS 
with minimum 50% overlap with a FP was considered to bind that region. 
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Though it is desirable to be able to pinpoint more specifically which regions to consider, it 
adds yet another technical step in which assumptions and approximations can exclude 
important information. 
4.3.6 DNA methylation 
As most epigenetic data available for CLL and MM is DNA methylation, we decided to focus 
on the lesser-explored side, the histone modifications and through those the regulatory 
elements. This both to add other information, and to restrict the number of methods 
performed, both from a sample availability and a method availably perspective. However, 
given that the state and fate of a cell is influenced by the interplay of all of these marks and 
forms of regulation, the absence of paired DNA methylation data for our samples could 
definitely be seen as a gap. During the review process of the MM paper, changes in 
regulatory element activity were overlapped with published changes in DNA methylation88, 
with a clear enrichment compared to random sampling. However, this is just a far 
approximation, and paired data, using the exact same patients and controls as in our studies, 
would have been a lot more informative. 
Also other forms of epigenetic regulation, like micro-RNAs and long non-coding RNAs, 
were not studied. 
4.4 BASIC DATA PROCESSING 
Many small decisions are made when selecting samples or filtering data, often without proper 
acknowledgement or discussion in final publications. This section touches on some of these 
steps, giving more background as to why these decisions were made and their possible 
implications. 
4.4.1 Filtering X and Y 
Handling X and Y chromosomes in next generation sequencing poses difficulties. First, given 
the partial similarities between both chromosomes, mapping is complicated due to multiple 
alignments, even in female individuals, were it is clear that reads mapping to the Y 
chromosome are technical errors. Standard procedures of removing ambiguously aligned 
reads will thus be targeting the sex chromosomes to a higher extend than other chromosomes. 
Additionally, the studies included here have only small sample sizes, and the included 
patients and healthy controls are not balanced when it comes to sex. Though technical 
solutions help to resolve the first issue100, the second would only be solved by the inclusion of 
extra, carefully selected subjects. Instead, we opted to remove both sex chromosomes to 
avoid false positive disease-related differences. However, both CLL and MM are more 
common in male patients, so sex differences do seem to be relevant to the diseases. This is 
important to keep in mind, and might limit the generalization capacities of the studies. On the 
other hand, it is in line with the aim to present the part of the disease that is consistent among 
all patients, no matter their genetic make-up, sex or age. 
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4.4.2 Normalization 
The absence, presence and type of normalizations used can have extensive influences on the 
results and validity of data analysis and, in the worst case, lead to different interpretation of 
the findings. This section gives some more explanation and reasoning behind the different 
basic forms of normalization used in the included works. It is important to note that 
differential analysis, performed by EdgeR and mostly through HOMER, was always 
performed on raw counts, as advised by the software.  
Correction for multiple testing RNA-seq, ChIP-seq and ATAC-seq datasets consist of 
many thousands of genes or peaks. For each of these, all samples (patients and controls) have 
counts, and thus for each gene or peak one can test if there is a statistical difference between 
cases and controls, resulting in a p-value. However, when putting all these thousands of tests 
together, p-values lose their meaning, and the total set no longer represents a 1% change (in 
case of p<0.01) that there actually is no difference between case and control, even if the test 
seems to find some. To remedy this one needs to correct for multiple testing. A standard 
correction is to use the FDR (False Discovery Rate), but in most cases we opted to go for the 
more conservative Bonferroni correction. In this case, each single p-value is multiplied by the 
total number of tests in the dataset, and then the cutoff of 0.01 is used on this corrected value.  
Log transformation The standard approach for all data in the included works was to get raw 
counts for all samples (not normalized), and then normalize the counts tables afterwards in R. 
The first normalization is a log10 or log2 transformation. Log transformation of sequencing 
data generally makes the distributions more normal, which makes them easier to handle, 
especially with statistics. To avoid issues with counts of 0 reads turning to –Inf after 
transformation, +1 was added to all counts prior to log transformation. It is also common to 
do log2 transformations instead of log10, which gives the same change in the shape of the 
distribution. Log2 lends itself easily to use with log2 fold changes, but it can be harder to 
have a feeling for the actual number.  
Quantile normalization The second step of standardization used was quantile normalization. 
Making the assumption that the majority of genes or regions do not change in expression, 
activity or accessibility, the overall distribution of the samples can be assumed similar. 
However, differences in for example sequencing depth can shift distributions, and thus 
similar number of reads can be incomparable between samples. Quantile normalization 
assumes that the distributions should be the same, and tries to pull the minimum, first 
quintile, medium, third quantile and maximum of different samples to the same level. 
However, it is important to keep in mind that, if the distributions are actually biologically 
different, this introduces bias by arbitrarily making them the same. However, we saw 
improvements in the biological interpretability of for example PCAs, making it likely that the 
normalization removed technical variation rather than biological (Figure 12). Of note, counts 
for SEs were not quantile normalized, since these are fewer and selected for regions that are 
exceptionally active or inactive in case and control, so no assumptions about overall stable 
distributions were made. 
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Figure 12: Raw and normalized reads for MM RNA-seq dataset, showing the improvement in read count 
distribution (left) and informative value of the data, as it reflects the biological populations (right). 
 
 
 
Figure 13: The effect of row normalization. Differentially expressed genes in Ibru dataset (Figure 2A in Ibru) 
illustrated as non-row normalized (left) and row normalized (right). Free clustering shows even more difference, 
but order of genes and samples used in the Ibru paper is preserved for ease of reference. 
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Row normalization In order to visualize genes or peaks with a wide range of read counts in 
a single plot, row normalization can help to show the differences one actually want to look at, 
which most often is the difference between samples, not between genes or peaks (Figure 13). It 
also influences the result in hierarchical clustering when plotting, and inherently removes any 
influence of gene or peak length. However, this means the info on the overall level of 
expression or activity is lost. In a row normalized heatmap, a gene changing from 5 reads to 
10 reads will look the same as one changing from 1000 to 2000 reads. 
4.4.3 Sample quality measures 
For the CLL and Ibru project, samples were considered outliers if a technical explanation 
could be found. Firstly, fastq files were checked for general quality using FastQC, from 
which samples with big problems, like extreme duplication rates, were flagged, excluded 
from further analysis and redone if material was available. Secondly, samples not reaching a 
minimal number of processed reads (mapped and deduplicated) were re-sequenced or 
excluded. Cut-offs were 10M for RNA-seq and ATAC-seq and 25M for histone ChIP-seq. 
Thirdly, ChIP-seq and ATAC-seq samples with low peak enrichment were redone or 
excluded. Though this can be seen from visually inspecting tracks in a genome browser, we 
decided upon a more objective cut-off based on “Approximate IP efficiency” value of 
HOMER peak finding output, where a minimal value of 10 was required. Finally, read 
distributions were compared per data type (Figure 14), and samples with widely aberrant 
distributions were removed from analysis. All of this assumes that the included samples are 
not wildly different in, for example, DNA content of the cells. Given that all included cells 
are human B-cells, we made the assumption they would be very similar in general, and 
extreme aberrations as listed above would be purely technical. In the HTCM project this was 
not the case, as low read numbers or aberrant distributions give information on the library 
quality, which is exactly what we wanted to measure there.  
 
Figure 14: Sample quality of CLL RNA-seq. Read count distribution (left) and PCA (right). 
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4.4.4 Number of identified elements 
Though it is natural to report the number of peaks, elements or genes one identifies or finds 
differential, it is a measurement that says just as much about the technological aspects of the 
data as about the biological ones. Even small differences in sample quality, lab efficiency, 
analysis settings etc. will give rise to different numbers. The influence of analysis decisions is 
exemplified in Table 5, which lists some H3K27ac ChIP-seq numbers for the CLL and MM 
studies, both having the same goal of looking at differences between healthy controls and the 
respective diseases. 
Table 5: Difference in identified and differential peaks between studies and questions. All selections of 
differential peaks (diff) are based on Bonferroni corrected p < 0.01, except for the example of fold change (FC) 
selection, in which case peaks with a change of minimum 2 fold were selected. 
H3K27ac peaks total diff %diff 
CLL vs ctrl 36594 3977 11% 
MM vs memB 80407 1200 1% 
(FC) MM vs memB 80407 20475 25% 
MM vs (memB or PB) 80407 2006 2% 
MM vs (memB and PB) 80407 201 0% 
 
Peak total Already for the total number of identified peaks, in other words, all peaks in any 
of the samples, be they from patients or healthy controls, there is a big difference between the 
CLL and MM studies. This could be due to any kind of variation, be it inter-personal, 
biological or technical. It could be because MM is known as a more heterogeneous disease, 
because the normal controls cover a wider range of B-cell development, the difference in 
sample numbers or peak calling methods, etc. As a result, the absolute number of reported 
changes can not be compared, even if they had been called with the same software and 
calculated in the same way, which was not the case. 
Use of controls As a start the CLL study considered all normal populations as one group of 
controls, asking for significant differences between all CLL and all controls. The MM study 
on the other hand kept the different populations of normal controls separate, so differences 
between MM and memB (memory B-cells, in the paper referred to as MB), PC (plasma cells) 
and PB (plasma blasts), were calculated separately. This might result in more stringency, but 
also a loss of statistical power, since it greatly reduces the number of controls for each 
question. So the 11% change in “CLL vs ctrl” compared to the 1% change in “MM vs MB” 
probably reflects the number of samples and the type of controls, rather than the biology. 
Fold change Additionally, the MM study mostly selected changes based on fold change (FC) 
rather than statistical tests and p-values. This is a very big conceptual difference, and again 
makes the numbers incomparable, as the same “MM vs MB” question results in a 1% 
statistical change, but a 25% change based on FC. As we directly noticed during the study, 
selections based on FC are very venerable to systematic biases in, for example, sequencing 
depth. Prior to proper normalizations, this had lead the study to very different conclusions. 
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4.4.5 Implications for comparing methods 
The HTCM paper assessed our improved version of the original ChIPmentation (CM) 
protocol98. This posed some specific issues, given that the difference in data quality between 
methods, and especially cell-numbers, was considerable. However, there was no point of 
removing low quality samples as described above, even if a technical explanation was readily 
found, as this is exactly what we wanted to describe. 
Library complexity The difference between the methods lies in the library preparation, 
where HTCM results in reduced loss of material, and thus gives more complexity in a library 
from the same number of cells (Figure 1F in HTCM). However, sequencing one sample deeper 
than another also results in more duplicate reads. In order to be fair to the different methods, 
each sample from a given cell-number, no matter the method, was down-sampled to the 
number of reads found in the sample with lowest sequencing depth.  
Normalization and filtering Most of the data handling was performed in line with the other 
project described in the sections above. However, HTCM and CM data was not quantile 
normalized, as we expect the read distributions to be widely different (Figure S2D in HTCM). 
Furthermore, no differential analysis was performed. Instead, we explored the number of 
detected peaks and their consistency between methods and cell-numbers. 
Number of peaks Yet again, the number of identified peaks in the samples does not say 
everything. When looking at the samples in genome browser, we could clearly see that some 
samples were better than others, still they ended up with similar number of total reads. This is 
why we introduced the cutoff for peak quality, where the number of high quality peaks, as 
reported by HOMER, was plotted in addition to just to total number (Figures S2B and S2C in 
HTCM). 
Peak overlap The fact that two methods find the same number of peaks does not mean that 
they find the same things. In line with the original CM paper, showing the overlap of peaks 
with regular ChIP-seq results, we described the overlap between our CM and HTCM results. 
Again, the focus was on high quality peaks, as they are the ones that we definitely want to 
retain between methods and cell-numbers (Figures 1D and 1H in HTCM).  
4.5 DATA INTEGRATION 
The CLL and MM papers make extensive use of data integration, given that they combine 
RNA-seq, ChIP-seq and ATAC-seq data. This sections highlights and contrasts some of the 
approaches. 
4.5.1 Combining RNA-seq and histone ChIP-seq 
The way regulatory elements were linked to their potential target genes differs between the 
MM and CLL papers. 
CLL Promoters were defined as all H3K27ac peaks closer than +-2kb of the TSS of an 
expressed gene. For distal elements on the other hand, TADs (Topologically Associated 
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Domains) were used instead of CTCF-domains. Publically available HiC data from the 
GM12878 cell line was used to call TADs. Within these, correlation values between gene 
expression and H3K27ac signal were calculated, and used to inform the decision (Figure 2 in 
CLL). Elements were assigned to their closest expressed gene, but only if they were 
significantly positively correlated. If they were not, the element was assigned to the highest, 
significantly correlated gene within the TAD. If no correlations were positive and significant, 
elements were left unassigned. SEs were simply seen as a combination of individual 
elements, such that a SE was assigned to all genes its individual enhancer or promoter peaks 
were assigned to. 
MM Regulatory elements closer than +-2 or 2.5kb were considered promoters. Distal 
regulatory elements were assigned based on a previous publication101, assigning within so 
called CTCF domains. These domains extend  +-200kb from the TSS of a gene, unless a 
CTCF site was crossed, in which case this became the domain border, as CTCF is assumed to 
work as an insulator. In contract to the original paper, the CTCF sites were not defined by 
ChIP-seq, but by overlapping CTCF motif scans with ATAC-seq peaks. Within these CTCF 
domains, elements that gained and lost activity were assigned to their closest gene. In the case 
of SEs, links were made by the ROSE software that called the SEs, and if a SE was linked to 
multiple genes, only the highest expressed was retained. 
This includes a lot of differences. The MM approach has the advantage not to include cell 
line data and issues in TAD calling, but is dependent on databases, success of motif scanning 
and introduces an arbitrary distance cutoff of 200kb. Assigning elements to the closest gene 
possibly leaves fewer elements unassigned, but ignores the fact that they often skip over 
genes and target more distal ones, and while correlation does not mean causation, it might 
add info linked to function. For all of these reasons and more, a myriad of linking variations 
can be found in the literature. 
4.5.2 Combining ATAC-seq and histone ChIP-seq 
Direct overlap of regions is pretty straightforward compared to combining expression with 
regulatory regions. Yet simple choices are made along the way, which do have implications 
for the results. 
CLL During the integration of ChIP-seq (H3K27ac and H3K4me2) and ATAC-seq peak 
catalogs, peaks were considered to overlap when the shared one base. It is to be questioned if 
this is biologically relevant, but given the relative uncertainty of the actual boundary of an 
element or binding location, we decided that it was enough. Since the reason for this overlap 
was to select regions open for binding in active regulatory elements, the main interest was the 
overlap between ATAC-seq and H3K27ac histone ChIP-seq. And surely, there are many of 
these elements. However, because we did full overlaps of all possible combinations of the 
three datasets, we could see that about 60% of ATAC-seq peaks do not fall within H3K27ac 
(Figure S1B in CLL). On top of that, the majority of those do not even fall within H3K4me2 
peaks. None of these regions, though they can differentiate between CLL and healthy 
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controls (Figure 15), were used for the rest of the analysis, as they were not within the focus of 
active regulatory elements, as marked by H3K27ac. Additionally it should be mentioned that, 
apart from this exploration exercise, the ATAC-seq peaks themselves were never considered 
again, but rather the footprints falling within them. 
MM In the MM paper, ATAC-seq peaks were only used by themselves. Integration with 
other datasets was only shown on footprint level, and focused on SEs rather than all 
H3K27Ac peaks. 
 
Figure 15: PCAs of CLL ATAC-seq based on overlap with H3K27ac (ac) and H3K4me2 ChIP-seq peaks 
(me2). Number of ATAC-seq peaks indicated above PCA. 
4.5.3 Transcription factor enrichment 
CLL Because we were initially looking for over-expressed TFs that clearly gained FPs, and 
under-expressed TFs that clearly lost FPs, enrichment was based on the difference between 
the number of gained and lost FPs that harbored a specific TF motif, and overlapped 
changing regulatory elements. Surprisingly, most TFs seem to have TFBSs falling in both 
gained and lost FPs, meaning that a low difference could point to either no changes, or very 
balanced changes. Additionally, absolute number of changes depends heavily on how easy it 
is to find the TFBS in the first place, as small motifs will have more hits over the genome, 
and thus will happen to fall in gained or lost FP more frequently than longer motifs do. For 
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this reason, the total number of TFBS for each TF was taken into account, no matter their 
overlap with FPs. 
MM In contrast to the CLL paper, the MM paper only considered FPs within +/- 5kb from 
the TSS of the 542 TFs for which TFBS were available and which were linked to SEs. This 
reduced the complexity considerably, and as a result no further enrichment was needed. 
4.5.4 Network approach 
Both the CLL and MM paper include a regulatory network, which are the accumulation of 
the precious sections. Next to the differences described there, both papers consider different 
elements, target genes, and scope meaning that the resulting networks in the MM paper 
(Figure 6 in MM) and CLL paper (Figure 7 in CLL) are not directly comparable. In an attempt to 
contrast them anyway, a schematic overview can be found in Table 6. In summary, the CLL 
network is a global network focusing on differences between CLL and healthy controls, 
describing how TF (families) target genes through regulatory elements. The MM paper 
includes a core regulatory network, focusing only on MM, describing how TFs target each 
other through SEs.  
Originally there was a second network in the MM paper, built from normal controls and 
constructed similarly to the MM diseased network, but it was not used in the publication. 
Instead, to contrast MM and healthy controls, simpler networks were built considering only 
regulation occurring around the TSS of the 542 included TFs, without additional information 
of regulatory elements. 
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Table 6: Comparison between CLL and MM network approaches. 
 CLL MM 
Network 
type 
Differential: 
network with changes between 
CLL and healthy subjects 
Descriptive: 
network for MM only 
Network 
scope 
Global: 
regulatory elements to genes 
Core regulatory circuit: 
SEs to TFs 
Network 
construction 
Single network 
build on integrated data from all 
patients and healthy controls 
Integration of 8 networks 
build on data from 8 MM patients 
Considered 
TFs 
88 enriched TFs (based on 
differential FPs in differential 
regulatory elements) 
TFs which were linked to SEs 
and for which TF motif scans 
were made 
Considered 
regulatory 
elements 
All differentially active regulatory 
elements 
All distal SEs +  
SE regions +/- 5 kb around the 
TSS of the considered TFs 
Considered 
target genes 
All differentially expressed genes The considered TFs 
Considered 
FPs 
All differential FPs (present in 
either CLL or healthy control) 
with TFBSs, falling in considered 
regulatory elements 
All FPs 
with TFBSs, falling in considered 
regulatory elements 
Solution to 
TF ambiguity 
TF families, suggesting high and 
differentially expressed members 
Random selection of highly 
expressed TF 
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5 RESULTS & DISCUSSION 
Methodological topics, many of which can be considered to be findings in themselves, have 
already been touched upon in the previous chapter. This one summarizes the main points of 
the papers included in this work, and discusses their relevance.  
5.1 CLL AND MM 
As CLL and MM are very similar kinds of projects, they will be discussed together. 
Consistent epigenetic patterns Both CLL and MM are genetically diverse, and MM even 
more so than CLL. Still, in both studies we found consistent changes in the use of regulatory 
elements, with thousands of elements showing consistently higher or lower activity in health 
than disease (Figures 3A in CLL and 1B in MM). On all levels available for the studies, be it 
expression (RNA-seq), establishment of regulatory elements (H3K4me2), activity of these 
elements (H3K27ac) or accessibility for TF binding (ATAC-seq), both CLL and MM datasets 
easily discriminated between healthy and diseased individuals (Figures 1G in CLL and S2C, S3D 
and S5B in MM). In the case of CLL, also the well-known clinically relevant subgroups of U-
CLL and M-CLL were readily distinguished, and related to their supposed cells of origin 
(Figure 5 in CLL). We found ATAC-seq data to be particularly discriminatory and consistent 
with current classification (Figure 1G in CLL), so one might consider using this type of data for 
an epigenetic-based classification effort. Though the number of samples was limited, some 
discrimination between CLL with or without trisomy 12 could be found (Figure 5A in CLL). 
We also showed the use of SEs in different settings in both CLL (Figure 4 in CLL) and MM 
(Figures 2, 3 and 6 in MM), and the de-compaction of heterochromatin in MM (Figure 4 in MM). 
Regulatory networks of disease In the CLL paper we show there is a vast amount of 
deregulation present in the wiring of CLL cells. The constructed networks suggest which TFs 
and TF families could be underlying the aberrant expression of hundreds of genes (Figures 7B 
and 7C in CLL), as highlighted in a selection of genes that are of great interest in CLL (Figure 
7D in CLL). For example, we showed that LEF1, a gene known to be up-regulated in CLL, has 
many CLL specific enhancers (Figure 1F in CLL), and through these is differentially targeted 
by TFs (Figures 7C and 7D in CLL). As mentioned in the previous chapter, the nature of the 
MM (SE-TF) network is different, and it does not contrast results with healthy controls, thus 
showing the totality of the regulation in de MM B-cells, not merely the aberrant part. We 
show that, for example, IRF4 is central to the MM network and highly expressed (Figure 6C in 
MM) in addition to being linked to MM specific SEs (Figure 2C in MM). This shows its 
aberrant regulation, and that it subsequently may deregulate the cell further, accumulating in 
the network found in MM. Furthermore, comparison of the complexity of promoter-TF 
networks in individual MM patients and normal controls shows the loss of network 
complexity in MM (Figure 5B in MM).  
Novelty For MM, the description of the thousands of consistently changed regulatory 
elements, based on RNA-seq, H3K27ac ChIP-seq and ATAC-seq, is novel information and 
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data, though maybe not surprising based on DNA methylation data and histone data from 
other malignancies. The de-compaction of heterochromatin is fully in line with the published 
observation of DNA hypomethylation in MM and cancer in general, which might make our 
observation more of a cancer conclusion than a MM specific concept. Still, it is a valuable 
additional resource now publically available for further exploration. For the CLL project, two 
very important papers have come out during the course of our research, which show a similar 
pattern, and include many more patients. The first was by Rendeiro et al,, publishing ATAC-
seq for 55 patients102. The second was by Beekman et al., publishing not only ATAC-seq, but 
also H3K27ac ChIP-seq on 107 CLL patients for which DNA methylation data was already 
available, and comparing it to healthy B-cells94. Their bigger dataset allowed them to not only 
see a tri12 specific pattern, but also changes present in case of specific recurrent mutations. 
From a reproducibility perspective this is great news, as it is in agreement with what we have 
found, and shows the general conclusions hold true on a bigger scale, and are not just a fluke 
of our dataset. The question remains how big the overlap between their and our stably 
changed elements is, which also holds true for the vast amount of DNA methylation data 
published on both disorders. 
Discussion After endless hunting for a genetic change that initiates all of the CLL or MM 
cases, and thus is present in all disease cases, it is very compelling to say that, among the 
consistent epigenetic patterns, we, meaning all researchers, have finally found the underlying 
mechanism for the diseases. However, there is nothing in this data that assures, or maybe 
even insinuates, that there is a causative relationship between the observed pattern and the 
initiation of the disease itself. What we are looking at is a relatively stable state, integrating 
everything from predisposition to initiation and progression, and in the case of CLL even 
different prior treatment regimes. So it might well be that, just to say it with a proverb, “all 
roads lead to Rome”. Still, it is plausible that random errors not only accumulate in the 
genome, but also the epigenome, and that multiple specific combinations of them ultimately 
result in one or the other disease. In light of this it would be interesting to see not only what is 
common between different patients or cohorts of the same disease, but also to overlap the 
CLL and MM data, and see how they relate to one another. 
Relevance The value of these works lies in the fact that they form great resources for further 
exploration. For example, the thousands of differential regulatory regions can be used to 
assess the possible importance of non-coding mutations, and, when adding the network 
information to this, even what the mutation’s effect could be. Similarly, it might be used to 
see if a gene recurrently targeted by deletion or mutation, but is genetically normal in a given 
patient, might be targeted by epigenetic deregulation instead. Combining all that data, all the 
ways in which genes can be recurrently targeted, could then lead to finding actual hits present 
in all patients with a disease, just on different levels that so far could not be tested, or were 
not integrated. Instead of genes being reported as x% recurrently mutated, we could add how 
often they are deleted, translocated, targeted by DNA methylation, histone modifications, 
micro-RNAs etc. This might well lead us to the original step on the figurative road to Rome. 
The networks could also be used by researchers working on a specific gene or TF, and could 
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suggest effects of removing any of the TFs and breaking the network in light of therapy. 
Integrated networks, build in similar ways for different diseases, could give insight in the 
workings of currently used drugs, and their transferability to other diseases. 
5.2 IBRU 
Early response We measured inflammatory cytokines in plasma, presence of cell-surface 
markers by flow cytometry and gene expression in lymph nodes (LN) and peripheral blood 
(PB) at multiple time points, ranging from before to 29 days (d29) after treatment with 
Ibrutinib. Already 9h after treatment, levels of multiple inflammatory markers are 
significantly altered in plasma, most of them showing reductions, with changes lasting at least 
until d29 post-treatment (Figure 1 in Ibru). Additionally, most of the expression changes in 
both PB and LM observed between pre-treatment and d29 samples are already visible from 
the earliest time point, in this case two days (d2) after treatment (Figure 2 in Ibru). Increase of 
total circulation lymphocyte counts is visible at 9h, but only significant from the d2 time 
point (Figure 3A in Ibru). 
Changes in LN last longer than in PB We show that the effect of Ibrutinib on expressional 
changes in LN stays stable or progresses further between d2 and d29 after treatment for 
almost all of the affected genes (Figure 2 in Ibru). However, though PB shows the same effects 
on d2, many of these changes revert back to pre-treatment levels by d29. 
Novelty Previous studies have shown reduction of cytokine levels in blood plasma upon 
longer periods of treatment with Ibrutinib, for example after 8 weeks103. We confirm these 
findings, and add information on the speed of the changes, as assessment of levels just hours 
after treatment with Ibrutinib is new. Similarly, the expression of selected genes has been 
assessed on time points similar to the ones in this work52, but RNA-seq, giving a much 
broader and unbiased view on the expression had not been done.  
Discussion Though we as humans would always like to have quick working solutions to our 
medical problems, if it is anything more than a headache we usually do not get what we want. 
However, on a cellular and molecular scale, things do happen fast. Upon treatment with 
Ibrutinib, patients can report an almost instant improvement, which, based on what is known 
about the phenomenon of redistribution lymphocytosis combined with our results, can 
definitely be more than just the thought of getting treatment. The total lymphocyte and CLL 
counts, combined with the literature, suggest that the RNA-seq pattern we observe, the 
stability of change in LN and the initial similar change of PB, which then reverts back to the 
original PB state, is exactly this process of redistribution lymphocytosis. From the total blood 
counts we can see that this happens within hours, and the dramatic changes within the first 
two days observed in RNA-seq suggest the same. It does not seem unreasonable to think that 
this redistribution is the reason for the improved well being reported by patients. In hindsight 
it would haven been better to have even earlier time points, as clearly a lot of the changes in 
plasma levels already happened before 9h, and in expression levels before d2. However, all 
changes observed in this study, both between compartments and between time points, are a 
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lot smaller than the changes observed between healthy and diseased samples in the CLL 
study. 
Relevance It is hard to argue that understanding more about the workings and effects of a 
drug currently used in treatment of patients could ever not be relevant. Be it for improved 
treatment regimes, handling of side-effects, its potential for combination therapy, its tendency 
to cause resistance or the development of new compounds, unraveling the relative mystery of 
why a lot of drugs work at all could be of great benefit. Also for basic research, studies of 
treatment are basically perturbation studies in the exact relevant complex system of a human 
body. This can help the understanding of complex concepts like relevance of the 
microenvironment, the mobility of cells and how they differ based on the compartment they 
are in, and so on. 
5.3 HTCM 
Faster We show that the original ChIPmentation (CM) protocol can be sped up by replacing 
the standard reverse crosslinking, which is often performed overnight, and DNA purification, 
adding another 1-2h, with a 5min step at 95°C in the PCR reaction that normally follows 
these procedures (Figures 1I and S1 in HTCM). We also show that, by reducing incubation 
times, the ChIP procedure itself can be shortened, making the whole HTCM procedure less 
than 24h (Figure 1I in HTCM), sequencing time included, without obvious loss of quality 
(Figures 1B and 1G in HTCM).  
Lower cell-numbers By eliminating the pre-amplification DNA purification, the HTCM 
protocol loses less material than the CM one. This results in more complex and better quality 
libraries from the same cell numbers (Figures 1B, 1F and S2 in HTCM). Consequently, HTCM 
allows for good quality data from lower starting cell-numbers than CM, with very good 
performance down to 2500 cells for the tested antibodies. At that level, 80% of the high-
quality peaks present in the reference sample (150k) are still detected, while CM needs 
between 10k and 50k cells, so about 10x more, to maintain the same retention of high quality 
peaks from its reference sample (Figure 1H in HTCM).  
Novelty The suggested HTCM protocol dramatically speeds up the originally published CM 
method98, in addition to realizing better quality libraries from lower cell-number due to its 
reduction in loss of material. After we had set up the method, we discovered that the 
suggested PCR based reverse crosslinking approach was used before in another variation on 
ChIP-seq, called LobChIP104. However, though it reduces time and losses at the reverse 
crosslinking stage, it does not include the advantages of tagmentation, and thus the overall 
process is not as fast and simple as HTCM.   
Discussion On multiple occasions, the CLL and MM paper highlight differences between 
primary samples and cell lines (GM12878 and MM.1S respectively), yet the HTCM paper 
was done on the MEC1 cell line. However, for this methodological proof of concept it was 
more important to have an unlimited amount of standardized cells, so the results could easily 
be reproduced by others, or compared to existing data. In hindsight it might have been 
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interesting to test the method on K562 cells instead of MEC1, as that was the cell line used in 
the original ChIPmentation paper. As mentioned in the chapter on methodological 
considerations, the HTCM method was not available at the time when the data for the CLL 
and MM papers was generated. Had it been, less cells of the available samples would have 
been needed for the generation of H3K27ac and H3K4me data, and we might have been able 
to generate complete data (RNA-, ChIP- and ATAC-seq) for more patients. Obviously, the 
use of this method does not solve the unspecific binding of low quality antibodies, so it does 
not quarantine that 2500 cells will be enough for any mark, on any cell type.  
Relevance With the use of next generation sequencing methods in clinical applications 
lurking around the corner, fast, high throughput and low input methods are very attractive. 
The speed means that results can be available the day after a clinical visit, and the scalability 
ensures that many patients, or many different ChIPed marks per patient, could be tested in 
parallel. Of course, this is not only useful in clinical practices, but also in basic or 
translational research. As illustrated by the CLL and MM studies, being able to get high 
quality data from fewer cells means more can be done with the same sample. Also for rare 
cell populations this is good news, as a couple of thousand cells can be enough for a decent 
HTCM sample. Additionally, the fact that it is easy to multiplex means screening for the 
binding of different TFs is a lot more feasible. In general, improving methods opens the door 
to new applications and research possibilities. 
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6 CONCLUSIONS 
The highlights of the different papers included in this work, as discussed in the previous 
chapter, are summarized in Figure 16. 
In the end, this journey is an exploration of what computational biology can mean for 
biological systems. The result is only ever maximally as good as its input. In this case it 
means that there is a focus on patients from highly developed countries with similar lifestyles, 
and that gender differences remain unexplored, possibly reducing the power for 
generalization. Yet, hopefully bioinformatic efforts like this can reduce the number of tests 
that need to be performed in the lab by providing some acceptable best guesses, especially in 
light of avoiding wasteful use of samples freely given by patients, or unnecessary breeding 
and sacrificing of animals. 
 
Figure 16: Summary of the different papers included in this work.
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7 POPULAR SCIENCE SUMMARY 
Every person has a very specific genetic code, present in all cells of your body and holding 
all the information that makes you… You. But still, you have a lot of different cell types. 
How does a stomach cell know that it should produce digestive acids, while a skin cell knows 
it shouldn’t? Why don’t the cells in your ears produce saliva? This is where gene regulation 
and epigenetics come in! It tells a cell which parts of its genetic code should be used at which 
times, and which ones it can totally ignore (like how the part on “how to produce saliva” is 
ignored by the cells in your ears).  
One of the less visible but important systems in your body is your immune system. The task 
of the immune system is to defend you against infections. It is made up of a bunch of 
different cell types circulating in your blood and keeping and eye on the rest of your body. 
Bye the way, did you know that all blood cells are made in the center of your bones? Pretty 
awesome if you ask me! Well, one specific set of immune system cells are the B-cells. They 
are the cells that get activated when you get a vaccination, and are exactly the ones that are 
studied in all of the papers in this thesis. When they get triggered, either by an actual 
infection or a vaccination, they help to clear the intruders from your body and build up a 
memory for this specific disease. In case you ever encounter it again, your body will be ready 
to get rid of the intruders so efficiently that you might not even notice you were infected at 
all. But, as with practically all cells in the body, sometimes things go wrong, and the cells can 
keep on growing and growing and become a cancer. When this happens to B-cells, there are 
multiple types of cancer you can get, and we have looked at two: chronic lymphocytic 
leukemia (CLL in short) and multiple myeloma (MM in short). The cancer cells grow so fast 
that they take over all the B-cell variation you are supposed to have (as shown in the colorful 
picture on the cover!). 
So, what have we found by doing all this research? In two of the studies included in this 
thesis we show that there are a whole bunch of regions in the genetic code of sick B-cells that 
get activated or deactivated in the diseases we studied (paper 1 and paper 4). Knowing these 
regions could help not just our understanding of regulation, but hopefully also give an idea on 
how to make the sick cells normal again, or how to make them disappear. We also looked at 
the changes in active genes and molecules in the blood after treatment of patients with one of 
the drugs currently used in the hospital. With many drugs, we know they work, and might 
have an idea on what the mechanism is, but don’t really know what physically happens to the 
body and the cells when people get treated. We saw there are some very early effects, were 
cells change which genes are active and move around in the body just hours or days after the 
patients got the drug (paper 2). And the last project included here is one where we suggest a 
faster and better method to look at some of the epigenetic changes, opening more doors for 
researchers to understand how cells work (paper 3). That’s it! 
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